Susceptibility of Mycobacterium abscessus to Antimycobacterial Drugs in Preclinical Models.

Related Articles

Susceptibility of Mycobacterium abscessus to Antimycobacterial Drugs in Preclinical Models.

Antimicrob Agents Chemother. 2015 Aug 24;

Authors: Obregón-Henao A, Arnett KA, Henao-Tamayo M, Massoudi L, Creissen E, Andries K, Lenaerts AJ, Ordway DJ

Abstract
Over the last 10 years, Mycobacterium abscessus group strains have emerged as important human pathogens which are associated with significantly higher fatality rate than any other rapidly growing mycobacteria. These opportunistic pathogens are widespread in the environment and can cause a wide range of clinical diseases including skin, soft tissue, central nervous system, and disseminated infections, by far the most difficult to treat is the pulmonary form. Infections with M. abscessus are often multi-drug-resistant (MDR) requiring prolonged treatment with various regimens and many times results in high mortality despite maximal therapy. We report here the evaluation of diverse mouse infection models for their ability to produce a progressive high level of infection with M. abscessus. The Nude, SCID, GKO and GMCSF knockout mice fulfilled the criteria for an optimal model for compound screening. Thus, we set out to assess the antimycobacterial activity of clarithromycin, clofazimine, bedaquiline, and clofazimine-bedaquiline combinations against M. abscessus infected GKO knockout and SCID murine infection models. Treatment of GKO and SCID mice with a combination of clofazimine and bedaquiline was the most effective in decreasing the M. abscessus organ burden.

PMID: 26303795 [PubMed - as supplied by publisher]